Epilepsy Research

Epilepsy is a group of neurological conditions consisting of recurrent, usually unprovoked epileptic seizures. Epileptic seizures have recently been defined as "a transient occurrence of signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain". Epilepsy is one of the most common disorders of the brain, with one in 10 people suffering at least one seizure in their lifetime. There are over 40 different types of epilepsy, each of which presents with its own unique combination of seizure type, typical age of onset, EEG findings, treatment, and prognosis.

Epilepsy Research Products Targets

Products for Epilepsy Research - Page 43

Cat.No. Product Name Information/Activity
BCC6578 O-Phospho-L-serine O-Phospho-L-serine is the immediate precursor to L-serine in the serine synthesis pathway, and an agonist at the group III mGluR receptors (mGluR4, mGluR6, mGluR7, and mGluR8); O-Phospho-L-serine also acts as a weak antagonist for mGluR1 and a potent antagonist for mGluR2.
BCC6975 (RS)-PPG (RS)-PPG is a potent and selective agonist for group III mGluRs. The EC50s of 5.2 μM, 4.7 μM, 185 μM, and 0.2 μM for hmGluR4a, hmGluR6, hmGluR7b, and hmGluR8a, respectively. Anticonvulsive and neuroprotective activity.
BCC7615 VU 0155041 1093757-42-6
BCC7642 VU 0155041 sodium salt 1259372-69-4
BCC7616 Z-Cyclopentyl-AP4 103439-17-4
BCC6872 CPPG CPPG ((RS)-CPPG) is a potent group II/III mGlu receptor antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC50=2.2 nM) over group II (IC50=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors.
BCC7528 MMPIP hydrochloride 479077-02-6
BCC6818 MPPG 169209-65-8
BCC7033 UBP1112 339526-74-8
BCC6150 TC-N 22A 1314140-00-5